Single-strain LBP
Single-strain LBP has been reported in various research areas, including cancer and digestive tract diseases. In cancer treatment, an LBP called MRx0518 has been developed based on Enterococcus gallinarum, which can be used in combination with the monoclonal antibody pembrolizumab to treat solid tumors. The mechanism of action involves the flagellin of MRx0518 activating TLR5 and nuclear factor kappa-B (NF-κB) receptors and inducing IL-8 production, leading to a strong anti-tumor response. An ongoing phase Ⅰ/Ⅱ clinical trial has shown promising results.
